Pacira BioSciences Inc. saw a director-initiated sale on March 17, 2026, when Mark Froimson disposed of 500 shares of the company s common stock, according to a Form 4 filed with the Securities and Exchange Commission. The sale executed at $21.81 per share produced proceeds of $10,905.
Following this transaction, Froimson directly holds 20,136 shares of Pacira. At the time of reporting, the company s stock was trading at $22.57 and Pacira s market capitalization stood at $917.5 million.
Market research available through InvestingPro is noted in the filing context: InvestingPro s analysis indicates the stock is currently assessed as undervalued on the basis of its Fair Value estimate. The platform also assigns Pacira a financial health score of GOOD and provides detailed Pro Research Reports for PCRX and more than 1,400 other U.S. equities.
Separately, Pacira s fourth-quarter 2025 results missed consensus forecasts on both earnings and revenue. The company reported earnings per share of $0.57, compared with an expectation of $0.90, a negative surprise of 36.67%. Reported revenue was $196.9 million, short of the expected $200.54 million, representing a revenue surprise of -1.82%.
Corporate governance pressure has intensified: activist investor DOMA Perpetual Capital Management LLC has nominated three candidates for election to Pacira s board, seeking leadership changes that include removal of CEO Frank Lee. Pacira confirmed receipt of these nominations and stated it has engaged with DOMA on multiple occasions since Lee s appointment as CEO in January 2024. The company also said that DOMA has not provided new strategic insights as part of those discussions. DOMA currently holds a 7.3% stake in Pacira.
The insider sale, the quarterly misses, and the activist nominations collectively keep Pacira under investor scrutiny. The Form 4 filing documents the director-level sale precisely as reported, while third-party research referenced in the filing frames valuation and financial health for interested investors.
Note: All transaction and financial figures above are reported as stated in regulatory filings and company disclosures.